Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis
Identifieur interne : 000612 ( Main/Exploration ); précédent : 000611; suivant : 000613Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis
Auteurs : Ra Ngala ; K. FiankoSource :
- African Health Sciences [ 1680-6905 ] ; 2013.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Ghana (épidémiologie), Humains, Hyperglycémie (sang), Hyperglycémie (épidémiologie), Hyperglycémie (étiologie), Hyperlipidémies (sang), Hyperlipidémies (épidémiologie), Hyperlipidémies (étiologie), Infections à VIH (), Infections à VIH (sang), Infections à VIH (traitement médicamenteux), Infections à VIH (épidémiologie), Lipides (sang), Mâle, Numération des lymphocytes CD4, Prévalence, Thérapie antirétrovirale hautement active (effets indésirables), VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études transversales.
- MESH :
- effets indésirables : Thérapie antirétrovirale hautement active.
- sang : Hyperglycémie, Hyperlipidémies, Infections à VIH, Lipides.
- traitement médicamenteux : Infections à VIH.
- épidémiologie : Ghana, Hyperglycémie, Hyperlipidémies, Infections à VIH.
- étiologie : Hyperglycémie, Hyperlipidémies.
- Adulte, Adulte d'âge moyen, Facteurs de risque, Femelle, Humains, Infections à VIH, Mâle, Numération des lymphocytes CD4, Prévalence, VIH-1 (Virus de l'Immunodéficience Humaine de type 1), Études transversales.
- Wicri :
- geographic : Ghana.
English descriptors
- KwdEn :
- Adult, Antiretroviral Therapy, Highly Active (adverse effects), CD4 Lymphocyte Count, Cross-Sectional Studies, Female, Ghana (epidemiology), HIV Infections (blood), HIV Infections (complications), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV-1, Humans, Hyperglycemia (blood), Hyperglycemia (epidemiology), Hyperglycemia (etiology), Hyperlipidemias (blood), Hyperlipidemias (epidemiology), Hyperlipidemias (etiology), Lipids (blood), Male, Middle Aged, Prevalence, Risk Factors.
- MESH :
- chemical , blood : Lipids.
- geographic , epidemiology : Ghana.
- adverse effects : Antiretroviral Therapy, Highly Active.
- blood : HIV Infections, Hyperglycemia, Hyperlipidemias.
- complications : HIV Infections.
- drug therapy : HIV Infections.
- epidemiology : HIV Infections, Hyperglycemia, Hyperlipidemias.
- etiology : Hyperglycemia, Hyperlipidemias.
- Adult, CD4 Lymphocyte Count, Cross-Sectional Studies, Female, HIV-1, Humans, Male, Middle Aged, Prevalence, Risk Factors.
Abstract
Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.
To determine the prevalence of lipid dysregulation and dysglycaemia in HIV infected patients on HAART in the Kumasi metropolis.
This cross sectional study was conducted between October 2009 and June 2010, and 305 HIV-infected patients consisting of 164 patients on HAART for at least six months and 141 HAART-naive patients constituted HIV-positive patients, not on HAART and whose CD4 were not below 320 cell/ml as the control. Data was analyzed using Graph Pad Prism (version 5.0). Unpaired t-test, linear and multivariate regression analyses, was used to predict glucose level from the various parameters. Anthropometric parameters consisting of body weight, waist and hip circumferences, height, bicep and triceps skin fold were measured with a pair of calipers. Lipid profile and fasting blood glucose were determined by enzymatic methods. CD4 counts and hemoglobin were determined.
Fasting plasma, glucose (3.81±0.08mmol/l, 4.48±0.17mmol/l), total cholesterol (3.05± 0.0 8mmol/l, 4.54±0.08mmol/l) LDL (2.24±0.07mmol/l, 2.87±0.07mmol/l) and HDL (0.85±0.04mmol/l, 0.97±0.03mmol/l) between the control and case respectively were significantly raised (P< 0.001), though within the physiological range. The significantly increased hip and waist circumferences, waist-to-hip ratio (0.85±0.22, 0.88±0.01) of the control and case correlated with lipodystrophy.
HAART was associated with lipodystrohy and, the risk of developing type II diabetes among the HAART experienced group was 5 times higher than the HAART naive group.
Url:
DOI: 10.4314/ahs.v13i4.35
PubMed: 24940339
PubMed Central: 4056472
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 000303
- to stream Pmc, to step Curation: 000302
- to stream Pmc, to step Checkpoint: 000310
- to stream PubMed, to step Corpus: 000301
- to stream PubMed, to step Curation: 000301
- to stream PubMed, to step Checkpoint: 000301
- to stream Ncbi, to step Merge: 000665
- to stream Ncbi, to step Curation: 000665
- to stream Ncbi, to step Checkpoint: 000665
- to stream Main, to step Merge: 000613
- to stream Main, to step Curation: 000612
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis</title><author><name sortKey="Ngala, Ra" sort="Ngala, Ra" uniqKey="Ngala R" first="Ra" last="Ngala">Ra Ngala</name><affiliation><nlm:aff id="A1"> Department of Molecular Medicine, Kwame Nkrumah University of Science &Technology</nlm:aff><wicri:noCountry code="subfield">Kwame Nkrumah University of Science &Technology</wicri:noCountry></affiliation></author><author><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><affiliation><nlm:aff id="A2"> Department of Biochemistry, Ghana Health Service</nlm:aff><wicri:noCountry code="subfield">Ghana Health Service</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">24940339</idno><idno type="pmc">4056472</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4056472</idno><idno type="RBID">PMC:4056472</idno><idno type="doi">10.4314/ahs.v13i4.35</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000303</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000303</idno><idno type="wicri:Area/Pmc/Curation">000302</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000302</idno><idno type="wicri:Area/Pmc/Checkpoint">000310</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000310</idno><idno type="wicri:source">PubMed</idno><idno type="wicri:Area/PubMed/Corpus">000301</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000301</idno><idno type="wicri:Area/PubMed/Curation">000301</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000301</idno><idno type="wicri:Area/PubMed/Checkpoint">000301</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000301</idno><idno type="wicri:Area/Ncbi/Merge">000665</idno><idno type="wicri:Area/Ncbi/Curation">000665</idno><idno type="wicri:Area/Ncbi/Checkpoint">000665</idno><idno type="wicri:doubleKey">1680-6905:2013:Ngala R:dyslipidaemia:and:dysglycaemia</idno><idno type="wicri:Area/Main/Merge">000613</idno><idno type="wicri:Area/Main/Curation">000612</idno><idno type="wicri:Area/Main/Exploration">000612</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis</title><author><name sortKey="Ngala, Ra" sort="Ngala, Ra" uniqKey="Ngala R" first="Ra" last="Ngala">Ra Ngala</name><affiliation><nlm:aff id="A1"> Department of Molecular Medicine, Kwame Nkrumah University of Science &Technology</nlm:aff><wicri:noCountry code="subfield">Kwame Nkrumah University of Science &Technology</wicri:noCountry></affiliation></author><author><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><affiliation><nlm:aff id="A2"> Department of Biochemistry, Ghana Health Service</nlm:aff><wicri:noCountry code="subfield">Ghana Health Service</wicri:noCountry></affiliation></author></analytic><series><title level="j">African Health Sciences</title><idno type="ISSN">1680-6905</idno><idno type="eISSN">1729-0503</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Antiretroviral Therapy, Highly Active (adverse effects)</term><term>CD4 Lymphocyte Count</term><term>Cross-Sectional Studies</term><term>Female</term><term>Ghana (epidemiology)</term><term>HIV Infections (blood)</term><term>HIV Infections (complications)</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (epidemiology)</term><term>HIV-1</term><term>Humans</term><term>Hyperglycemia (blood)</term><term>Hyperglycemia (epidemiology)</term><term>Hyperglycemia (etiology)</term><term>Hyperlipidemias (blood)</term><term>Hyperlipidemias (epidemiology)</term><term>Hyperlipidemias (etiology)</term><term>Lipids (blood)</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Risk Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Humains</term><term>Hyperglycémie (sang)</term><term>Hyperglycémie (épidémiologie)</term><term>Hyperglycémie (étiologie)</term><term>Hyperlipidémies (sang)</term><term>Hyperlipidémies (épidémiologie)</term><term>Hyperlipidémies (étiologie)</term><term>Infections à VIH ()</term><term>Infections à VIH (sang)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (épidémiologie)</term><term>Lipides (sang)</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>Thérapie antirétrovirale hautement active (effets indésirables)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études transversales</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Lipids</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antiretroviral Therapy, Highly Active</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>HIV Infections</term><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Thérapie antirétrovirale hautement active</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>HIV Infections</term><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Hyperglycemia</term><term>Hyperlipidemias</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Hyperglycémie</term><term>Hyperlipidémies</term><term>Infections à VIH</term><term>Lipides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Hyperglycémie</term><term>Hyperlipidémies</term><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Hyperglycémie</term><term>Hyperlipidémies</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>CD4 Lymphocyte Count</term><term>Cross-Sectional Studies</term><term>Female</term><term>HIV-1</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prevalence</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Facteurs de risque</term><term>Femelle</term><term>Humains</term><term>Infections à VIH</term><term>Mâle</term><term>Numération des lymphocytes CD4</term><term>Prévalence</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term><term>Études transversales</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Ghana</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><sec><title>Background</title><p>Diet and genetic predisposition significantly affect lipid metabolism in the individual. This metabolic effect is further challenged in patients infected with HIV and on HAART. The prolonged use of HAART is associated with lipodystrophy, dyslipidemia, and insulin resistance.</p></sec><sec><title>Objective</title><p>To determine the prevalence of lipid dysregulation and dysglycaemia in HIV infected patients on HAART in the Kumasi metropolis.</p></sec><sec sec-type="methods"><title>Methods</title><p>This cross sectional study was conducted between October 2009 and June 2010, and 305 HIV-infected patients consisting of 164 patients on HAART for at least six months and 141 HAART-naive patients constituted HIV-positive patients, not on HAART and whose CD4 were not below 320 cell/ml as the control. Data was analyzed using Graph Pad Prism (version 5.0). Unpaired t-test, linear and multivariate regression analyses, was used to predict glucose level from the various parameters. Anthropometric parameters consisting of body weight, waist and hip circumferences, height, bicep and triceps skin fold were measured with a pair of calipers. Lipid profile and fasting blood glucose were determined by enzymatic methods. CD4 counts and hemoglobin were determined.</p></sec><sec sec-type="results"><title>Results</title><p>Fasting plasma, glucose (3.81±0.08mmol/l, 4.48±0.17mmol/l), total cholesterol (3.05± 0.0 8mmol/l, 4.54±0.08mmol/l) LDL (2.24±0.07mmol/l, 2.87±0.07mmol/l) and HDL (0.85±0.04mmol/l, 0.97±0.03mmol/l) between the control and case respectively were significantly raised (P< 0.001), though within the physiological range. The significantly increased hip and waist circumferences, waist-to-hip ratio (0.85±0.22, 0.88±0.01) of the control and case correlated with lipodystrophy.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>HAART was associated with lipodystrohy and, the risk of developing type II diabetes among the HAART experienced group was 5 times higher than the HAART naive group.</p></sec></div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Fianko, K" sort="Fianko, K" uniqKey="Fianko K" first="K" last="Fianko">K. Fianko</name><name sortKey="Ngala, Ra" sort="Ngala, Ra" uniqKey="Ngala R" first="Ra" last="Ngala">Ra Ngala</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaGhanaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000612 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000612 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaGhanaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= PMC:4056472
|texte= Dyslipidaemia and dysglycaemia in HIV-infected patients on highly active anti-retroviral therapy in Kumasi Metropolis
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24940339" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a SidaGhanaV1
| This area was generated with Dilib version V0.6.31. |  |